NervGen Pharma
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2955 Virtual Way Ste 480, Vancouver, Bri...Phone Number
(778) 731-1711Website
www.nervgen.comRevenue
-Stock Symbol
NGENIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About NervGen Pharma
NervGen is restoring life's potential by developing innovative solutions for the treatment of nervous system injuries. The Company is developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer's disease. NervGen's platform technology targets protein tyrosine phosphatase sigma ("PTP"), a neural receptor that impedes nerve repair. Inhibition of the PTP receptor has been shown to promote regeneration and remyelination of damaged nerves, as well as improvement of nerve function in animal models for various medical conditions.Explore more
NervGen Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NervGen Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NervGen Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NervGen Pharma has new funding data
Check out if NervGen Pharma is spiking on competitors!
Product Launch: Get notified when NervGen Pharma launches new products
NervGen Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if NervGen Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on NervGen Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NervGen Pharma
Recommended Actions
Reach out to Masked Content who joined NervGen Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to NervGen Pharma
Compare insights from companies similar to NervGen Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NervGen Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NervGen Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NervGen Pharma.
NervGen Pharma financials insights
Gather financial insights about NervGen Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$15M
2024
Stock Offering
$16.9M
NervGen Pharma Tech Stack
A closer look at the technologies used by NervGen Pharma
See more technologies
Most Recent Scoops
Event
Person-Based
Events, Pharmaceuticals, Podcast
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
NervGen Pharma News & Media
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at aNervGen Announces Proposed Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-fundNervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company’s financial strategy and operations, incl
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding NervGen Pharma
Sign Up For FreeTo access detailed company insights
NervGen is restoring life's potential by developing innovative solutions for the treatment of nervous system injuries. The Company is developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer's disease. NervGen's platform technology targets protein tyrosine phosphatase sigma ("PTP"), a neural receptor that impedes n... Read More
